Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1528-3658
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics ; volume:24 ; number:1 ; day:24 ; month:9 ; year:2018 ; pages:1-15 ; date:12.2018
Molecular medicine ; 24, Heft 1 (24.9.2018), 1-15, 12.2018
- Creator
-
Runcie, Karie
- Contributor
-
Budman, Daniel R.
John, Veena
Seetharamu, Nagashree
SpringerLink (Online service)
- DOI
-
10.1186/s10020-018-0051-4
- URN
-
urn:nbn:de:101:1-2018110722032404404237
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Runcie, Karie
- Budman, Daniel R.
- John, Veena
- Seetharamu, Nagashree
- SpringerLink (Online service)
Other Objects (12)
Bi-specific Aptamers mediating Tumour Cell Lysis
Developing novel specific therapeutics targeting adipocytes
Immunogenicity Risk Assessment for Multi-specific Therapeutics
Cell-type specific potent Wnt signaling blockade by bispecific antibody
Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy
Design and Evaluation of Tumor‐Specific Dendrimer Epigenetic Therapeutics
Polyclonal tumor-specific activation of cytotoxic effector cells by bispecific antibody constructs
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Structural insights into the bi-specific cross-over dual variable antibody architecture by cryo-EM
Targeting the Tie2–αvβ3 integrin axis with bi-specific reagents for the inhibition of angiogenesis
A bi-specific lectin from the mushroom Boletopsis grisea and its application in glycoanalytical workflows
Bi-specific Aptamers mediating Tumour Cell Lysis
Developing novel specific therapeutics targeting adipocytes
Immunogenicity Risk Assessment for Multi-specific Therapeutics
Cell-type specific potent Wnt signaling blockade by bispecific antibody
Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy
Design and Evaluation of Tumor‐Specific Dendrimer Epigenetic Therapeutics
Polyclonal tumor-specific activation of cytotoxic effector cells by bispecific antibody constructs
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Structural insights into the bi-specific cross-over dual variable antibody architecture by cryo-EM
Targeting the Tie2–αvβ3 integrin axis with bi-specific reagents for the inhibition of angiogenesis
A bi-specific lectin from the mushroom Boletopsis grisea and its application in glycoanalytical workflows
Bi-specific Aptamers mediating Tumour Cell Lysis
Developing novel specific therapeutics targeting adipocytes
Immunogenicity Risk Assessment for Multi-specific Therapeutics
Cell-type specific potent Wnt signaling blockade by bispecific antibody
Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy
Design and Evaluation of Tumor‐Specific Dendrimer Epigenetic Therapeutics
Polyclonal tumor-specific activation of cytotoxic effector cells by bispecific antibody constructs
T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Structural insights into the bi-specific cross-over dual variable antibody architecture by cryo-EM
Targeting the Tie2–αvβ3 integrin axis with bi-specific reagents for the inhibition of angiogenesis